Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE I/II CLINICAL TRIAL OF SYS6055 INJECTION FOR THE TREATMENT OF RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase I/II clinical trial (SYS6055-003) of SYS6055 Injection (the "**Product**") developed by the Group for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma has been officially initiated at the first centre in China.

The Product is an *in vivo* CAR-T product. By directly generating CAR-T cells targeting CD19 *in vivo* through lentiviral vectors, it can specifically recognise and eliminate target cells, thereby achieving a therapeutic effect. Compared with traditional CAR-T products, the Product offers potential clinical advantages in medication cost, accessibility and immediacy. Previously, the Product demonstrated a favourable safety profile and preliminary efficacy signals in a Phase I/II clinical trial involving participants with relapsed/refractory aggressive B-cell lymphoma. This trial is still ongoing.

In October 2026, the Group received the Notice of Approval for Clinical Trial of Drug issued by the National Medical Products Administration of the People's Republic of China and, following the approval, initiated the SYS6055-003 clinical trial, aiming to explore the safety, tolerability, pharmacokinetic profile and preliminary efficacy signals of the Product in participants with relapsed/refractory B-cell non-Hodgkin lymphoma. Currently, the recruitment and screening of participants are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 6 November 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.